We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BYOT Byotrol Plc

0.075 (14.29%)
07 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.075 14.29% 0.60 2,337,424 12:28:03
Bid Price Offer Price High Price Low Price Open Price
0.55 0.65 0.60 0.55 0.55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chemicals & Chem Preps, Nec 4.59M -1.69M -0.0037 -1.62 2.72M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:31:26 O 200,000 0.649 GBX

Byotrol (BYOT) Latest News (4)

Byotrol (BYOT) Discussions and Chat

Byotrol Forums and Chat

Date Time Title Posts
09/8/202207:34TRADING4GOOD FROM LSE 2
13/4/202020:14Byotrol (BYOT) One to Watch on Wednesday 2
27/2/201619:04Byotrol:::::::::Cleaning Up45

Add a New Thread

Byotrol (BYOT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Byotrol (BYOT) Top Chat Posts

Top Posts
Posted at 07/12/2023 08:20 by Byotrol Daily Update
Byotrol Plc is listed in the Chemicals & Chem Preps, Nec sector of the London Stock Exchange with ticker BYOT. The last closing price for Byotrol was 0.53p.
Byotrol currently has 453,890,405 shares in issue. The market capitalisation of Byotrol is £2,723,342.
Byotrol has a price to earnings ratio (PE ratio) of -1.62.
This morning BYOT shares opened at 0.55p
Posted at 07/12/2023 11:15 by mudbath
Byotrol's decimated share price reflects the significant possibility that a delisting lies ahead.
When/if announced the share price could well implode even further.
Therein would lie the main opportunity.
Posted at 30/11/2023 13:16 by sikhthetech

"They have called out disappointing sales in Human Healthcare in H1"

I warned about low consumer sales over 3 years ago, when you were misleading readers about sales, Finncap being conservative etc

I take it you're not looking for an excuse to sell. That'll be disgraceful behaviour wouldn't it?

Try and be honest for once.
I see you/your mates are ramping HVO, Polb, SLN, TRMR.

Given you portray yourself as a well researched poster, why do the vast majority of your shares crash after you have ramped them? You make a dodgy 2nd hand car salesman sound honest. How many multiple ids do you have and why?

sikhthetech - 04 Dec 2022 - 20:27:36 - 10513 of 12322 BYOTROL-CAN DELIVER AMAZING RESULTS - BYOT
"I think Amazon is a relatively new endeavour for byotrol."

It's jam tomorrow.
As you very well know during the biggest pandemic to hit the world in 100yrs, Byot had a £590k (yes k) increase in GLOBAL consumer sales. And that was because there was a world wide shortage so people had no alternative.

As I said at the time, the pandemic was the golden opportunity presented on a plate but they missed it.
Consumer sales a virtually non-existent and therefore jam tomorrow.

Your jam tomorrow is endless and repeated every few months for years but never materialised.

Btw how did Hycolin do on Amazon despite being originally listed last year??? You're very selective in your comments and have a selective memory depending on your agenda, which currently is ramping.

H1 results possibly due this week. Best see what they say rather than baseless jam tomorrow fro (if going by last year)

sikhthetech - 07 Jan 2021 - 14:57:21 - 7339 of 8923

Facts from their H1-2021 accounts published last month. Rest is jam tomorrow.

£590k (yes k) increase in global consumer sales when there's the biggest pandemic to hit the globe is not impressive.

So with the biggest pandemic to strike in a century they managed £997k (ex-royalty & licensing) of consumer sales!
That includes Boots, Homeandcleaning, direct website sales, global sales.


"H1 revenues more than doubled to £1.01m from £0.41m, including a small amount of IP-based income, versus nil IP income in the comparable period. Gross profit (on products) increased to £0.43m from £0.17m. "
"Elsewhere, sales across existing customers all increased in this segment, especially into Japan via our longstanding agents in pet and healthcare."

1gw - 16 Nov 2023 - 12:28:44 - 12222 of 12322 BYOTROL-CAN DELIVER AMAZING RESULTS
They have called out disappointing sales in Human Healthcare in H1
Posted at 02/11/2023 07:39 by brownson
It would be nice to see a comment from the company “ we are aware of recent share price ………;……̷0;…….. etc etc”

The problem is DT never managed to maintain the share price and he’s now back in charge. Finding a CEO will take months and it’s unlikely to be anyone with any great stature
Posted at 26/10/2023 12:34 by loafofbread
2 weeks before he left he was still buying shares and owns 1.5% so alongside the rest of the BOD plenty to lose unless they sort this out.

My take is someone is booking the loss for 28% CGT offset.

Byotrol PLC

08 September 2023

Byotrol Plc

("Byotrol" or the "Company")

Director Dealing

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, announces that on the 8(th) of September 2023, the wife of Vivan Pinto, CEO of the Company, purchased a total of 400,000 ordinary shares of 0.25p each ("Ordinary Shares") at an average price of 1.65p per Ordinary Share (the "Purchase").

Following the Purchase, Vivan Pinto's beneficial holding (including those held by his wife) is 2,900,000 Ordinary Shares, representing 0.64% of the total voting rights of the Company. As announced on 28 July 2022, Vivan Pinto subscribed for convertible loan notes in the Company, which if converted would represent an additional 0.7% of the total voting rights of the Company.
Posted at 25/10/2023 12:38 by riddlerone
This is why I and many others on this board appreciate and respect 1gw's research

1gw - 23 May 2023 - 15:27:59 - 11175 of 11929 BYOTROL-CAN DELIVER AMAZING RESULTS - BYOT
Well done byotrol on (apparently) beating Solvay to the EPA residual virucidal registration.

Now does that unlock any minimum guaranteed payments from USCo?

Then the following day

Byotrol PLC US EPA approves Byotrol24 as long-lasting virucide (5499A)
24/05/2023 3:14pm
UK Regulatory (RNS & others)

Thank you 1gw for doing what you do..
Posted at 08/9/2023 11:56 by loafofbread
At least we know where our supply of Brown seaweed will be coming from and our first partnership/development partner.

06 July 2023

Byotrol Plc

("Byotrol" or the "Company")

Patent Granted for Novel Anti-viral Seaweed Extract

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to report the approval today of a UK patent following its discovery of unique anti-viral properties of certain enhanced extracts of commonly available brown seaweed.

The award is a result of many years of research by Byotrol's technical team at its laboratories at Thornton Science Park, a University of Chester campus, and has been supported by the research scientists at the University of Liverpool led by Professor James Stewart, and by funding received from the Biotechnology and Biological Sciences Research Council (BBSRC) and Innovate UK.

The grant of the patent application gives Byotrol validated, valuable and protected intellectual property, to support the development of commercial relationships.

In the UK and Europe, seaweed extracts are not as yet approved as active materials for biocidal products, Byotrol's established area of expertise. So, we are now actively exploring alternative applications in very sizeable markets such as over-the-counter (OTC) products for the prophylactic treatment of viral conditions including colds, flu, coronaviruses and cold sores.

Byotrol Plc's Chairman, Dr Trevor Francis, comments:

"We are delighted to have secured the first patent for our seaweed-based anti-viral technologies. It is another good indication of the quality of our technical capability, and it will most certainly help us as we intensify the search for commercial partners. It also adds to our already significant level of intellectual property in antimicrobials.

"This patent further confirms Byotrol's commitment to developing and commercializing natural and sustainable antimicrobial actives."
Posted at 23/8/2023 06:03 by football
Todays RNs Wednesday

Byotrol PLC Investor Presentation via Investor Meet Company
23/08/2023 7:00am
RNS Non-Regulatory


Byotrol PLC

23 August 2023

RNS Reach

Byotrol plc

("Byotrol" or the "Company")

Investor Presentation via Investor Meet Company

Byotrol plc (AIM: BYOT), the specialist infection prevention and control company is pleased to announce that Vivan Pinto, CEO, David Traynor, Executive Director, and Chris Sedwell, CFO, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 8th Sep 2023 at 11:00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet BYOTROL PLC via:

Investors who already follow BYOTROL PLC on the Investor Meet Company platform will automatically be invited.

For further information, visit , follow on twitter @byotrol, or contact
Posted at 01/8/2023 14:07 by sikhthetech
What's funny is that they have a 'new' professional sales team.
What sort of team have they had for the last 20yrs?

As I said at the time, they should have had a placing and setup their business to take advantage of the pandemic.
Covid was nearly 3 years ago, they should have been prepared for it after the Swine Flu Epidemic some 14yrs ago. If not then they should have set it up quickly in 2020.

1gw is all hindsight and clueless how a business should be run.

sikhthetech - 26 Oct 2021 - 18:57:43 - 8940 of 10283

You're clueless, as the company newsflow...

The time for a placing was last year, March-April, in the middle of the 1st lockdown. Byot knew in March sales rose significantly. March, there was a lockdown and by April it was clear there was a pandemic. So I think a placing March-April would have been well received by IIs and PIs, as was the case with many other companies. The share price end of March was around 5p, so around current share price

April 2020:
"We continue to experience exceptional demand for our technologies across all our markets due to the covid19 pandemic. We expect this to continue for at least the first quarter of FY2021 and likely beyond,
and are now expecting to benefit significantly from a secular shift towards the heightened importance of infection prevention, cleanliness and hygiene, whether personal, institutional or environmental."

It isn't hindsight either as you wrongly claim, on 17th March 2020, I posted the following.
What part of the highlighted sentence don't you understand???

sikhthetech - 17 Mar 2020 - 20:12:36 - 4993 of 8940
The problem isn't it's effectiveness, it's their supply chain, their marketing.

Posted at 27/6/2023 07:04 by 1gw
best - I think this is just the nature of the game in FMCG. Product claims are vital to marketing and product ingredients may be regarded as trade secrets, except to the extent that they have to be disclosed for regulatory reasons (e.g. "active" ingredients).

If byotrol knows that Dettol 24 is an Actizone product because Solvay has told it so under the terms of a non-disclosure agreement then byotrol can't share that with shareholders (without Solvay's agreement). If byotrol doesn't know that Dettol 24 is an Actizone product then byotrol is presumably free to share its informed opinion that it looks like an Actizone product. So do shareholders actually want byotrol to ask Solvay (and then be bound by the NDA) given the weight of evidence that Dettol 24 is an Actizone product?

What byotrol should be doing is trying to track penetration of Dettol 24 and estimate sales so that it can sense-check statements of sales issued by Solvay to byotrol under the commission agreement.
Posted at 18/3/2023 11:20 by mudbath
Byotrol has 40 employees as quoted in the 2022 Annual Report. (1gw)

Surely, for a £7million M/Cap company with revenues also of circa £7nillion that level of staffing is both outlandish and unsustainable, when compared to say Tristel.

The BYOT increasing cash usage reflects this human resource cost, with 2022 year end balance of £1.1 million subsequently increased by a further £1million (convertible loan receipt) being notably eroded to just £1.2 million at the interim stage.Given a similar decline, cash might be in the region of £300k at this months year end.

It could be that another raise is looming, possibly paired with a strategic review.
The current BYOT share price weakness is possibly reflecting these concerns.

No bargain then, until such time as Byotrol can demonstrate some (any) momentum.
Byotrol share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |